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Santiago Grijalvo, Manuel Nieto-Díaz, Rodrigo M. Maza, Ramón Eritja,
and David Díaz Díaz*
Alginate (ALG) is a lineal hydrophilic polysaccharide present in brown algae
cell walls, which turns into a gel state when hydrated. Gelation readily
produces a series of three dimensional (3D) architectures like ﬁbers,
capillaries, and microspheres, used as biosensors and bio-actuators in a
plethora of biomedical applications like drug delivery and wound healing.
Hydrogels have made a great impact on regenerative medicine and tissue
engineering because they are able to mimic the mechanical properties of
natural tissues due to their high water content. Recent advances in
neurosciences have led to promising strategies for repairing and/or
regenerating the damaged nervous system. Spinal cord injury (SCI) is
particularly challenging, owing to its devastating medical, human, and social
consequences. Although eﬀective therapies to repair the damaged spinal cord
(SC) are still lacking, multiple pharmacological, genetic, and cell-based
therapies are currently under study. In this framework, ALG hydrogels
constitute a source of potential tools for the development of implants capable
of promoting axonal growth and/or delivering cells or drugs at speciﬁc
damaged sites, which may result in therapeutic strategies for SCI. In this
mini-review, the current state of the art of ALG applications in neural tissues
for repairing the damaged spinal cord is discussed.
1. Introduction
The use of hydrogels provides a broad range of possibilities
in biomedicine, ranging from cell and gene therapy,[1,2] and
drug delivery,[3] to regenerative medicine and tissue engineering
applications.[4–7] The success of this technology derives from the
ability of hydrogels to retain high levels of water, as much as
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over 99%, which favors the entrapment
of biological entities and increases their
biocompatibility.[8]
Synthetic (e.g., 2-hydroxyethyl methacry-
late [HEMA], polyacrylamide [PAA],
polyethylene glycol [PEG]) and natural poly-
mers (e.g., alginate [ALG], carrageenan,
chitosan, hyaluronic acid) have been used
in appropriate concentrations to trigger
gelation processes by applying chemical or
physical cross-linking strategies.[9] These
two processes permit the self-assembly of
such polymers into hydrophilic networks,
giving rise to a plethora of 3Dmaterials con-
taining both strong and weak interactions
throughout polymer networks.
Although synthetic polymers have played
a meaningful role in multiple biomedi-
cal applications,[10,11] extensive studies have
led to natural polymer-based hydrogels
emerging as equally or more suitable ma-
terials, due to their low immunogenic-
ity, ready biodegradability, and easy large-
scale production.[12,13] To this end, speciﬁc
polysaccharide-based hydrogels are being engineered. They
prove to be eﬃcient depots for living cells, small molecules,
growth factors, and liposomes, for use in a wide range
of biomedical applications including cell transplantation or
drug delivery. Hydrogels,[14] in particular those composed of
ALG,[15,16] have recently[17–21] emerged as bridging materials
capable of delivering cells and drugs into speciﬁc locations,
thus promoting tissue regeneration when implanted in injured
tissues.[22]
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1.1. Spinal Cord Injury
The brain together with the spinal cord (SC) forms the central
nervous system (CNS), which integrates information and coordi-
nates activity across the entire body. Spinal cord injury (SCI) is
a dreadful disorder that aﬀects more than 180 000 people world-
wide every year, causing permanent disability—including loss of
sensory and motor functions in trunk and limbs, together with
the loss of autonomous regulation of breathing, bladder empty-
ing, and sexual function.[23]
Traumatic injury to the SC leads to a complex pathophysiol-
ogy that aﬀects the neural, vascular, and immune systems and
largely determines the functional outcome from the SCI. The
trauma damages the membranes of spinal cord cells, mainly
in the gray matter, causing cell death, axotomy, and blood ves-
sel rupture.[24] The initial damage may consist of rupture of the
blood–spinal cord barrier, ionic disbalance, massive excitatory
neurotransmitter release, oxidative stress, inﬂammation, and im-
mune response, among others. Themolecular and cellular events
triggered by such damage induce cell death among neurons and
glial cells for weeks after injury, and extend the damage to re-
gions far from the injury epicenter.[25,26] The cellular responses
lead to the formation of a glial scar that reestablishes the blood–
brain barrier and isolates the damaged region, where cysts usu-
ally form. Functional deﬁcits due to SCI are usually permanent
because the regenerative response of the injured neurons is very
limited,[27,28] and regenerating axons are exposed to inhibitory
molecules,[29] glial scars, and cysts that prevent growth across the
injury site.[30]
Despite the resources and eﬀorts applied in research to seek
an eﬃcient therapy to restore loss of function, only rehabilita-
tion and epidural electrical stimulation[31] have proven eﬀective
in recovering the functional deﬁcits of SCI. Signiﬁcant eﬀorts
have been made to develop therapeutic strategies aiming to pro-
tect spared tissue and replace lost cells, promote axonal growth
and myelination, and restore or replace lost neural signaling.
In this context, novel therapeutic treatments involving regener-
ative medicine and tissue engineering have emerged as promis-
ing strategies focused on promoting axon growth and/or deliv-
ering cells or drugs to speciﬁc damaged sites for SCI. These
approaches rely on using cell transplantation procedures, anti-
oxidative or anti-inﬂammatorymolecules, speciﬁc growth or neu-
rotrophic factors, as well as biomaterial scaﬀolds. The positive
outcomes achieved in vitro and in vivo have facilitated launch-
ing various pre-clinical and clinical controlled trials to validate
such therapeutic eﬀectiveness, giving rise to promising therapeu-
tic strategies for SCI.[32–36]
1.2. Hydrogel-Based Materials in SCI and Neural Regeneration
The rapid development and extensive research sustained by poly-
mer science have facilitated the appropriate design and prepara-
tion of a large number of scaﬀolds for tissue engineering appli-
cations. Both synthetic and natural materials have demonstrated
their usefulness to reconstruct and replace the great majority
of damaged tissues.[6,7,37] To do so, preformed materials should
fulﬁll a series of requirements to be considered as optimal im-
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plants for promoting SC repair and neural tissue engineering.
These include their lack of toxicity and immunogenicity, thus
contributing to high biocompatibility.[38,39] Appropriate degrada-
tion rates,[40] shear modulus, substrate stiﬀness, and superﬁcial
geometry are important properties that should also be taken into
account.[40]
A good number of 3D materials and drug delivery devices
in conjunction with injectable hydrogels have been properly de-
signed for SCI.[16,39,41–44] Some non-degradable materials com-
posed of synthetic polymethacrylates have shown notable success
as implants due to their stiﬀness without causing compression
of the SC tissue.[44] This feature makes non-degradable materials
favorable to cell encapsulation and to providing the proper 3D
networks for bridging neural tissues.[45,46]
Degradable synthetic polymers like PEG and poly-peptide
hydrogels,[47–49] among many others,[50–53] have emerged as
promising alternatives for reconstructing damaged tissues.[44]
This is mainly due to optimizing several parameters like molec-
ular weight, degree of crosslinking, or polymer structures, which
tend to favor surface degradation rates and consequently the ab-
sence of immune response in the body and nerve compression
after the scaﬀold implantation.[54,55] A selection of other synthetic
Biotechnol. J. 2019, 14, 1900275 1900275 (2 of 8) © 2019 The Authors. Biotechnology Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.com
Table 1. Use of alginate (ALG) as a natural hydrogel involved in neural tissue engineering applications such as axon growth, cell-based therapies, drug
delivery, and 3D bioprinting.
Entry Application Material Model Comments Reference
1 Axon growth ALG-poly-l-ornithine and
laminin
In vitro and in vivo (Fischer
344 rats)
The material was ﬁlled with
astrocytes and was able to
integrate into the damaged site
[77]
2 Axon growth Capillary ALG hydrogel Schwann cells encapsulation
(primary culture) and in vivo
(Fischer 344 rats)
Axon growth was signiﬁcantly
increased when BDNF is
expressed
[78]
3 Axon growth ALG-PHB coated with
ﬁbronectin
In vivo (adult female
Sprague-Dawley rats)
The presence of PHB and ﬁbronectin
aided regeneration and supported
neuronal survival
[79]
4 Cell-based therapy Unmodiﬁed soft ALG
hydrogel
In vivo (Wistar rats) Material was implanted, leading to
improved locomotor recovery
[80]
5 Cell-based therapy ALG hydrogel was covalently
modiﬁed with RGD
In vitro (2D culture and 3D
culture)
The RGD modiﬁcation improved the
Schwann cells attachment
[81]
6 Cell-based therapy Ionically cross-linked
unmodiﬁed ALG hydrogel
In vitro (primary neurons in 3D
culture)
The material was able to promote
neuritogenesis, exhibiting good
viability and cell proliferation
[82]
7 Cell-based therapy ALG anisotropic capillary In vivo (Fischer 344 rats) Bone marrow stromal cells
expressing a neurotrophic factor
were seeded
[83]
8 Drug delivery ALG microﬁbrous patches
(a drug delivery platform)
Local delivery of Rolipram.
Characterization of in vitro
and in vivo models (athymic
rats)
Those animals treated with the
prepared patches exhibited greater
functional recovery than controls
[84]
9 3D-scaﬀold ALG-gelatin blends Printability tests for bioprinting.
Cell in vitro studies
(mesenchymal stem cells)
A general study in which 7% ALG
and 8% gelatin gave rise to high
printability rates and stiﬀness
[85]
10 3D-scaﬀold Neurocompatible 3D-ALG
“living” scaﬀold combined
with methylcellulose
Cell lines used: primary human
neonatal ﬁbroblasts,
hiPSC-derived ventral sNPCs,
and miPSC-derived OPCs
A 3D-spinal cord tissue model
resulted in successful modeling
of CNS tissue
[86]
hydrogels used for SC regeneration[56–59] have been listed in Table
S1, Supporting Information.
Extensive eﬀorts have been also made to use natural hydrogels
in SC repair.[60–67] Natural materials made up of ALG, agarose,
cellulose, chitosan or hyaluronic acid, among others, have been
used in vitro and in vivo with the aim of promoting cell adhesion,
controlled and localized delivery of neurotrophic factors, cell de-
livery (including pluripotent or multipotent stem cells), or the
formation of ﬁlament bridges and scaﬀolds for neurite regrowth.
[3,12,13,16,21,68] Unlike synthetic polymers, natural implanted mate-
rials display high biocompatibility in living tissues. In this way,
the cytotoxicity and immune response exhibited by these mate-
rials are practically zero.[69] Recent uses of natural hydrogels are
listed in Table S1, Supporting Information.
Taking advantage of the characteristics of synthetic and natural
hydrogels, a combination of bothmaterials has been proposed for
attempting SC regeneration. The idea of using synthetic/natural
hydrogels is not novel, as they are employed in other biomedi-
cal applications.[70,71] In particular, this strategy involves putting
the most common features of both hydrogels into practice: bio-
compatibility and biodegradability in the case of natural hydro-
gels and the ability to “tune” the physical and mechanical prop-
erties of the resultant materials when using synthetic hydrogels.
This combination allows the preparation of functionalized ma-
terials to provide protection at the injured site as well as deliver
neurotrophic factors and neural stem cells.[72–76] Detailed infor-
mation on the progress and uses of these composites is shown
in Table S1, Supporting Information.
In this article, we aim to review the current state-of-the-art
strategies employed to prepare natural hydrogels for neural tis-
sue engineering applications. Particularly, this revision is focused
on ALG as an artiﬁcial scaﬀold, analogous to the ECM used in
regenerative applications to repair the damaged SC. The possi-
bilities of ALG for promoting axon growth, cell-based therapies,
drug delivery, or as a 3D-scaﬀold will be discussed below, and are
displayed in Table 1.
2. Alginate Biomaterials for the Repair of the
Injured Spinal Cord
ALG is a hydrophilic lineal polysaccharide naturally occurring
in the cell walls of brown algae. ALG consists of repeated units
of (1-4)-𝛽-d-mannuronic acid and 𝛼-l-guluronic acid building
blocks. These residues are found as ﬂexible coils in aqueous so-
lution. The presence of divalent cations (e.g., Ca2+, Mg2+, Ba2+,
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and many others) is essential for the chelation process amid
the two aforementioned building blocks. As a consequence, co-
operative ionic inter-chain forces are spontaneously produced,
giving rise to ordered 3D structures that cause gelation of the
ALG solution.[87] Physical properties of the resultant hydrogels
(e.g., mechanical strength, stability or elasticity) can also vary, de-
pending on the divalent cation used. This tunable property fa-
cilitates engineering diﬀerent ALG-based materials used in nu-
merous minimally invasive biomedical applications, from oral
administration to hydrogel injection. Versatility, high biocompat-
ibility and lack of toxicity, ease of gelation, and external structural
similarity to the extracellular matrix (ECM) of living tissues are
key properties of ALG for biomedical applications. However, de-
spite ALG being a biocompatible and naturally derived hydrogel,
some impurities isolated in commercially available samples have
proved to be cytotoxic and mitogenic.[88,89] This might lead to un-
wanted responses after cell transplantation, reducing its potential
use unless a prior puriﬁcation of the commercial sample is car-
ried out.[88]
ALGhas proven to be an eﬃcient biomaterial and amodel scaf-
fold when working as a bridging material in neural tissue engi-
neering, including SCI and peripheral nerve regeneration, aswell
as in the delivery of cell and growth factor molecules (EGF and
bFGF) for SC repair.[90–95]
2.1. 3D-Scaﬀolds
3D-scaﬀolds have resulted in a prominent strategy for CNS re-
generation, as they can facilitate cell proliferation and provide
cellular adhesion onto the newmaterial.[96] Hydrogelsmay confer
additional advantages as cell and molecule delivery vehicles, due
to their high water content and good response to several stimuli
like pH or temperature. Natural polymers like chitosan, agarose,
ﬁbrin, collagen, gellan-gum, Matrigel, and hyaluronic acid have
been used as 3D scaﬀolds to aid in soft-tissue reconstructions
of the injured ECM of the SC, through ﬁlling cavities arising
from the injury.[97–105] To accomplish this, such bio-scaﬀolds have
been successfully engineered. They exhibit tubular-like struc-
tures, besides containing some components of the ECM, includ-
ing hyaluronic acid[106] and ﬁbronectin.[107]
3D-bioprinting has recently emerged as a potential technique
with numerous therapeutic applications, including neural tissue
engineering.[108] Alginate has been used in the search of bioinks
for 3D-bioprinting applications.[85] On this point, soft ALG hy-
drogels have proved to be eﬃcient as a bioink for 3D bioprint-
ing experiments to provide an appropriate scaﬀold to accommo-
date neuronal cells. These uses are favored by their biocompati-
ble and biodegradable properties in contact with nerve tissues. To
achieve this, diﬀerent viscosities of ALG were tested and mixed
with methylcellulose (MC) in a 1:3 volume ratio (ALG:MC) to
ﬁnd the most suitable ink composition for printing.[86] This strat-
egy allowed a microenvironment to be created by preparing a
3D SC-based platform containing neuronal and oligodendrocyte
progenitor cells. Interestingly, both progenitor cells were able
to proliferate precisely, showing the usefulness of this platform
in modeling CNS tissue architectures. Besides MC, other addi-
tives like ﬁbrin,[109] chitosan, or genipin[110] have been also tested
to produce useful bioinks and 3D-bioscaﬀolds for neural tissue
engineering.[111]
2.2. Axon Growth
In the past century, Aguayo and colleagues demonstrated that
SC axons can regenerate if provided with the appropriate
substrate.[112,113] Since then, many laboratories have explored the
possibilities of biomaterials to build up scaﬀolds that support
and promote axonal growth across the injury region. Biomate-
rials should have thin walls with appropriate diameters, capa-
ble of promoting axon growth and orientation in the SC.[22,42]
The generation of cross-linked ALG-based capillaries has facil-
itated preparing materials with various channel diameters (11,
13, 29, and 89 µm), according to the divalent cation used in vitro
(Ba2+, Ca2+, Sr2+, and Zn2+, respectively). In this regard, Pawar
and coworkers showed that axon density growth within hydrogel
strongly depended on the channel diameter, which ranged from
10 to 100 µm, whereas a decrease in the linear orientation of such
axons was obtained with increasing channel diameter.[114]
Not only unmodiﬁed anisotropic scaﬀolds have been used as
promising implants to be integrated into the SC without detect-
ing any inﬂammatory responses. Recently, alternative attempts
involving the modiﬁcation of anisotropic ALG capillary surfaces
with cationic polymers (poly-l-ornithine, PLO) and laminin have
resulted in enhanced axonal growth and cellular adhesion, af-
ter 2 weeks of incubation in vitro.[77] These positive responses
were replicated in adult rats after implanting this PLO-laminin-
ALG hydrogel scaﬀold, which promoted cell migration and slight
axon growth throughout the capillary channels. Notably, the au-
thors observed that neurite growth was signiﬁcantly improved in
the presence of cationic peptides when additional astrocytes were
ﬁrst seeded within the material before grafting.
A combined therapy involving the transplantation of ALG cap-
illary hydrogels containing Schwann cells followed by the in-
jection of a neurotrophic factor (BDNF) as a supplementary
growth stimulus facilitated the regeneration of axons at the le-
sion site. Injection into the caudal spinal parenchyma led to sig-
niﬁcant regeneration, compared to transplants that lacked BDNF
(Figure 1).[78] The positive eﬀect promoted by BDNF after SCI
was also observed by Novikov et al., when used a biodegrad-
able synthetic implant made up of ﬁbers containing poly-𝛽-
hydroxybutyrate (PHB).[79] These PHB ﬁbers were coated with
neonatal Schwann cells as well as a combination of ALG and ﬁ-
bronectin. The resultant 2–3 mm long matrix was evaluated in
vivo and surprisingly showed neuronal survival and axonal re-
generation after its implantation in the lesion site.
2.3. Cell-Based Therapy
Embryonic, pluripotent, neural, and mesenchymal stem cells as
well as Schwann cells, neurons, and other neural cells have been
transplanted into speciﬁc damaged areas to replace lost neu-
ral cells, protect the surviving ones, and facilitate regenerative
processes.[31,115] However this strategy, though promising, faces
the risk of poor cell survival after transplantation.[116]
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Figure 1. Lesion paradigm and experimental procedures. A) Schematic
diagram of the experimental design. A 1.5–2 mm long segment of the SC
was removed unilaterally at the C5 level before implanting a Schwann cells
(SCs)-seeded alginate scaﬀold. Subsequently, viral vectors (yellow) for the
regulatable expression of green ﬂuorescent protein (GFP) (rAAV5- GFP)
or BDNF (rAAV5-BDNF) were injected into the caudal SC, ipsilateral to
the lesion. SCs (blue) were also injected into the caudal SC in one group.
Biotinylated dextran amine (BDA, red) was injected in the SC rostral to
the lesion to trace descending axons 3 or 7 weeks post-lesion. A1) Cross-
sectional and A2) longitudinal view of the capillary lumen. B) After a hemi-
section lesion (arrowhead, ≈2 mm in length) of the rat SC, C) the alginate
scaﬀold loaded with SCs (white arrow) was grafted into the lesion and D)
virus (*) or SCs (black arrow) were injected into the SC caudal to the scaf-
fold, using a glass capillary. Scale bar: 300 µm in (A1); 500 µm in (A2).
Reproduced with permission[78]. Copyright 2017, Elsevier.
Figure 2. Alginate reduces ﬁbrous scarring. Examples of hematoxylin &
eosin (H&E) stained tissue sections 140 days after SCI of 2 mm size. A)
Overview of a cross section of control SC. B) Magniﬁcation of the area
indicated by the black box showing the ﬁbrotic scar and adjacent SC tissue.
C) Overview of a cross section of SC that received an alginate implant.
D) Magniﬁcation of the area indicated in (C) by the black box illustrating
the lack of a ﬁbrous scar. Reproduced with permission[80]. Copyright 2018,
Springer Nature.
In this regard, ALG has proved to be eﬃcient as a soft hy-
drogel material capable of adhering to and protecting neurons
when acting as an implant. Furthermore, such ALG implants
have also favored functional recovery, particularly in the locomo-
tor system after SCI[80] (Figure 2), including the outgrowth of ax-
ons in the presence of some divalent cations (e.g., Ca2+, Ba2+, or
Sr2+).[117,118]
Unfortunately, poor adhesion properties have also been re-
ported when Schwann cells are seeded onto the above-mentioned
ALG scaﬀolds.[81,119] To avoid this limitation and achieve superior
adhesiveness, both the preparation of ionically ultrasoft cross-
linked ALG hydrogels[82] and modifying the ALG surface with
a argininylglycylaspartic acid tripeptide (RGD) peptide[81] led to
cell proliferation and facilitated Schwann cell adhesion in 3D cell
cultures.
Alginate scaﬀolds have been also used as an appropriate depot
for bone-marrow stromal cells (BMSCs). These cells were embed-
ded into a 2 mm-long capillary hydrogel and ﬁnally implanted to
evaluate the release of neurotrophic factors (BDNF).[83] Data con-
ﬁrmed ALGwas able to integrate into the SC lesion without toxic-
ity, favoring axonal regeneration. Encouragingly, survival of BM-
SCs and proliferation of Schwann cells and blood vessels were
observed when compared to ALG-based biomaterials containing
only BMSCs.
Recent studies carried out by Wen et al. showed the feasibil-
ity of modifying ALG hydrogels with an integrin ligand (𝛼3𝛽1).
This 3D culture system proved to be eﬃcient in favoring the en-
capsulation and diﬀerentiation of neural progenitor cells (NPCs)
in vitro, after a 3-month incubation.[120] These authors used
surface plasmon resonance (SPR) to measure the speciﬁc in-
teractions between the integrin ligands and the NPCs. This 3D
platform also enabled diﬀerentiation of both mouse and human
NPCs into the distinct neural cell types, after being entrapped
within ALG hydrogel.
2.4. Drug Delivery
Available evidence has demonstrated that drugs and bioac-
tive molecules, such as nucleotides and proteins, can help re-
pair the damaged SC, promoting neurogenesis, plasticity, or
regeneration.[121–126] Hydrogels have been employed to deliver
many of these molecules to target tissues and cells under precise
conditions. For example, interesting strategies have been pro-
posed to achieve controlled release of rolipram—a blood-brain
barrier permeable neuroprotectant with signiﬁcant eﬀects on
functional recovery after SCI[127]—and increase its therapeutic ef-
fects at the action site. In this direction, Downing and cowork-
ers prepared series of ALG microﬁbrous patches for the con-
tinuous delivery of rolipram in vivo, achieving good therapeu-
tic results (Figure 3).[84] Improvements in the functional recov-
ery of motor function after injury were observed (open-ﬁeld loco-
motion, forelimb articular movement, and animal coordination)
when small doses of rolipram were released (≈60 µg cm−2) over
12 days through the material. In contrast, when authors used
high-doses of rolipram under regular administration conditions,
a pronounced decline in animal survival rates (up to 50%) was
observed.
3. Conclusions and Future Perspectives
The use of ALG-based hydrogels faces a good number of chal-
lenges but also opportunities for tissue repair and regenerative
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Figure 3. Implantation of drug-eluting microﬁbrous patches after SCI. A)
Schematic of subdural implantation of drug-eluting microﬁbrous patches
into the injured cord. B) Macroscopic view of lesion site and patch during
animal surgery. An asterisk was used to mark location of drug-eluting mi-
croﬁbrous patch. C,D) Gross histology of SC cross section 8 weeks post
SCI. H&E staining reveals new tissue formation at the lesion site and
patch’s ability to integrate into the surrounding tissues (D). C) Less re-
generated control for comparison. Here, arrows point to the implantation
site for drug-elutingmicroﬁbrous patches. Red dashes outline areas of less
tissue formation for comparison. Reproduced with permission[84]. Copy-
right 2012, Elsevier.
medicine. The structure, physical properties, and speciﬁc func-
tions of hydrogels may vary when tuning these materials. Ben-
eﬁcial properties such as biocompatibility, long-term stability
in vivo, or their suitability to be chemically modiﬁed with appro-
priate ligands, make these materials promising scaﬀolds for em-
bedding drugs, nerve cells, growth factors, etc.
The use of ALG-based hydrogels in regenerative medicine has
grown exponentially in the last decade, achieving signiﬁcant and
promising results as shown by a good number of in vivo models.
However, the translational step from the bench with new designs
of materials for the injured CNS in the ﬁeld of tissue engineering
to implementing an eﬀective treatment in humans is still a daunt-
ing challenge. Promotion of axon regeneration and neural cell
replacement after SCI by means of ALG and other biomaterials
has been addressed through a variety of strategies, for instance
embedding and subsequent cell release, the use of neurotrophic
factors, and small drug molecules.
In a plethora of in vitro and in vivomodels, the development of
these combined strategies has shown greater therapeutic eﬀec-
tiveness than those involving single treatments.[128] The design
and development of new biodegradable materials capable of en-
trapping stem cells and/or therapeutic drugs could enhance this
combinatorial approach, providing maximal functional recovery
and the highest chance of success in the clinic. Regrettably, a full
understanding of biomaterial properties as well as choosing the
right therapeutic combination (e.g., stem cells, neurotrophic fac-
tors, or small drugs) requires great investigation in depth, so as
to improve the relevant translational research.
In addition to using cell therapy and biomaterials for treat-
ing SCI, tissue engineering oﬀers alternative technologies like
3D-bioprinting and microﬂuidic devices. These are emerging as
potential applications for replacing tissues and creating disease
models aimed at developing further new therapies and also un-
derstanding more precisely the behavior of the disorder.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
Acknowledgements
M.N.-D. and R.M.M. contributed equally to this work. This re-
search was funded by the Spanish Ministerio de Ciencia e Inno-
vación (MICINN), grant number CTQ2017-84415-R; CIBER-BBN, grant
number CB06_01_0019; the Generalitat de Catalunya, grant number
2017/SGR/114; and the Junta de Comunidades de Castilla La Man-
cha, grant number SBPLY/17/180501/000376. The authors thank Guido
Vaughan Jones Carter (IPNA-CSIC) for manuscript proofreading.
Conﬂict of Interest
The authors declare no conﬂict of interest.
Keywords
alginate, biomaterial, bioprinting, central nervous system, neural tissue
engineering, regenerative medicine, spinal cord injury
Received: June 14, 2019
Revised: October 12, 2019
Published online: November 14, 2019
[1] C. Wang, R. R. Varshney, D.-A. Wang, Adv. Drug Delivery Rev. 2010,
62, 699.
[2] R. L. Youngblood, N. F. Truong, T. Segura, L. D. Shea, Mol. Ther.
2018, 26, 2087.
[3] E. Larrañeta, S. Stewart, M. Ervine, R. Al-Kasasbeh, R. F. Donnelly,
J. Funct. Biomater. 2018, 9, 13.
[4] B. V Slaughter, S. S. Khurshid, O. Z. Fisher, A. Khademhosseini, N.
A. Peppas, Adv. Mater. 2009, 21, 3307.
[5] J.-H. Lee, H.-W. Kim, J. Tissue Eng. 2018, 9, 2041731418768285.
[6] E. Jabbari, Gels 2019, 5, 30.
[7] E. S. Place, J. H. George, C. K. Williams, M. M. Stevens, Chem. Soc.
Rev. 2009, 38, 1139.
[8] J. Fu, M. In Het Panhuis, J. Mater. Chem. B 2019, 7, 1523.
[9] J. Maitra, V. K. Shukla, Am. J. Polym. Sci. 2014, 4, 25.
[10] O. Wichterle, D. Lím, Nature 1960, 185, 117.
[11] M. C. Hacker, J. Krieghoﬀ, A. G. Mikos, in Principles of Regenerative
Medicine, 3rd ed., (Eds: A. Atala, R. Lanza, A.G. Mikos, R. Nerem),
Academic Press, Boston 2019, pp. 559–590.
[12] J. Pushpamalar, A. K. Veeramachineni, C. Owh, X. J. Loh,
ChemPlusChem 2016, 81, 504.
[13] S. Grijalvo, J. Mayr, R. Eritja, D. D. Díaz, Biomater. Sci. 2016, 4, 555.
[14] R. Y. Tam, T. Fuehrmann, N. Mitrousis, M. S. Shoichet, Neuropsy-
chopharmacology 2014, 39, 169.
[15] L. N. Novikova, A. Mosahebi, M. Wiberg, G. Terenghi, J.-O. Kellerth,
L. N. Novikov, J. Biomed. Mater. Res., Part A 2006, 77A, 242.
Biotechnol. J. 2019, 14, 1900275 1900275 (6 of 8) © 2019 The Authors. Biotechnology Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.com
[16] G. Perale, F. Rossi, E. Sundstrom, S. Bacchiega, M. Masi, G. Forloni,
P. Veglianese, ACS Chem. Neurosci. 2011, 2, 336.
[17] R. Barbucci, M. Consumi, S. Lamponi, G. Leone, Macromol. Symp.
2003, 204, 37.
[18] N. B. Shelke, R. James, C. T. Laurencin, S. G. Kumbar, Polym. Adv.
Technol. 2014, 25, 448.
[19] J. Radhakrishnan, A. Subramanian, U. M. Krishnan, S. Sethuraman,
Biomacromolecules 2017, 18, 1.
[20] A. Kirschning, N. Dibbert, G. Dräger, Chem. - Eur. J. 2018, 24, 1231.
[21] T. Coviello, P. Matricardi, C. Marianecci, F. Alhaique, J. Controlled
Release 2007, 119, 5.
[22] Q. Zhang, B. Shi, J. Ding, L. Yan, J. P. Thawani, C. Fu, X. Chen, Acta
Biomater. 2019, 88, 57.
[23] M. Nieto-Díaz, F. Esteban, D. Reigada, T. Muñoz-Galdeano, M.
Yunta, M. Caballero-López, R. Navarro-Ruiz, Á. del Águila, R. Maza,
Front. Cell. Neurosci. 2014, 8, 53.
[24] M. G. Fehlings, A. R. Vaccaro, M. Boakye, Essentials of Spinal Cord
Injury: Basic Research to Clinical Practice, Thieme, New York 2012.
[25] M. J. Crowe, J. C. Bresnahan, S. L. Shuman, J. N. Masters, M. S.
Beattie, Nat. Med. 1997, 3, 73.
[26] X. Z. Liu, X. M. Xu, R. Hu, C. Du, S. X. Zhang, J. W. McDonald, H.
X. Dong, Y. J. Wu, G. S. Fan, M. F. Jacquin, C. Y. Hsu, D. W. Choi, J.
Neurosci. 1997, 17, 5395.
[27] M. Murray, I. Fischer, Neurosci. 2001, 7, 28.
[28] W. Plunet, B. K. Kwon, W. Tetzlaﬀ, J. Neurosci. Res. 2002, 68, 1.
[29] M. L. Condic, M. L. Lemons, Neuroreport 2002, 13, A37.
[30] J. W. Fawcett, R. Asher, Brain Res. Bull. 1999, 49, 377.
[31] F. B. Wagner, J. B. Mignardot, C. G. Le Goﬀ-Mignardot, R. Demes-
maeker, S. Komi, M. Capogrosso, A. Rowald, I. Seáñez, E. Piron-
dini, M. Vat, L. A. McCracken, R. Heimgartner, I. Fodor, A. Watrin, P.
Seguin, E. Paoles, K. Van Den Keybus, G. Eberle, B. Schurch, E. Pra-
long, F. Becce, J. Prior, N. Buse, R. Buschman, E. Neufeld, N. Kuster,
S. Carda, J. Von Zitzewitz, V. Delattre, T. Denison, et al.,Nature 2018,
563, 65.
[32] J. D. Steeves, D. Lammertse, A. Curt, J. W. Fawcett, M. H. Tuszynski,
J. F. Ditunno, P. H. Ellaway, M. G. Fehlings, J. D. Guest, N. Kleitman,
P. F. Barlett, A. R. Blight, V. Dietz, B. H. Dobkin, R. Grossman, D.
Short, M. Nakamura, W. P. Coleman, M. Gaviria, A. Privat, Spinal
Cord 2007, 45, 206.
[33] H. Hasebe, M. Ito, inMetals for Biomedical Devices, 2nd ed. (Ed: M.
Niinomi), Woodhead Publishing Series in Biomaterials, Woodhead
Publishing, Cambridge, UK 2019, pp. 475–493.
[34] H. Zhao, Q.-L. Sun, L.-J. Duan, Y.-D. Yang, Y.-S. Gao, D.-Y. Zhao, Y.
Xiong, H.-J. Wang, J.-W. Song, K.-T. Yang, X. M. Wang, X. Yu, Eur.
Spine J. 2019, 28, 1092.
[35] A. D. Levi, K. D. Anderson, D. O. Okonkwo, P. Park, T. N. Bryce, S. N.
Kurpad, B. Aarabi, J. Hsieh, K. Gant, J. Neurotrauma 2019, 36, 891.
[36] S. Han, W. Yin, X. Li, S. Wu, Y. Cao, J. Tan, Y. Zhao, X. Hou, L. Wang,
C. Ren, J. Li, X. Hu, Y. Mao, G. Li, B. Li, H. Zhang, J. Han, B. Chen,
Z. Xiao, X. Jiang, J. Dai, J. Neurotrauma 2019, 36, 2316.
[37] Y. D. Taghipour, N. Asadi, V. R. Hokmabad, A. R. D. Bakhshayesh,
N. Asadi, R. Salehi, H. T. Nasrabadi, Curr. Med. Chem. 2019, 26,
https://doi.org/10.2174/0929867326666190711103956.
[38] O. Alluin, C. Wittmann, T. Marqueste, J.-F. Chabas, S. Garcia, M.-N.
Lavaut, D. Guinard, F. Feron, P. Decherchi, Biomaterials 2009, 30,
363.
[39] Š. Kubinová, Neurochem. Res. 2019, 1. https://doi.org/10.1007/
s11064-019-02808-2. [Epub ahead of print]
[40] D. Shahriari, J. Koﬄer, D. A. Lynam,M. H. Tuszynski, J. S. Sakamoto,
J. Biomed. Mater. Res., Part A 2016, 104, 611.
[41] M. Tsintou, K. Dalamagkas, A. M. Seifalian, Neural Regener. Res.
2015, 10, 726.
[42] K. S. Straley, C. W. P. Foo, S. C. Heilshorn, J. Neurotrauma 2010, 27,
1.
[43] D. Macaya, M. Spector, Biomed. Mater. 2012, 7, 012001.
[44] R. C. Assunção-Silva, E. D. Gomes, N. Sousa, N. A. Silva, A. J. Sal-
gado, Stem Cells Int. 2015, 2015, 948040.
[45] Š. Kubinová, D. Horák, A. Hejcˇl, Z. Plichta, J. Kotek, E. Syková, J.
Biomed. Mater. Res., Part A 2011, 99A, 618.
[46] Z. Cai, Y. Gan, C. Bao, W. Wu, X. Wang, Z. Zhang, Q. Zhou, Q. Lin,
Y. Yang, L. Zhu, Adv. Healthcare Mater. 2019, 8, 1900013.
[47] Z. Hassannejad, S. A. Zadegan, A. R. Vaccaro, V. Rahimi-Movaghar,
O. Sabzevari, Injury 2019, 50, 278.
[48] K. J. Lampe, R. G. Mooney, K. B. Bjugstad, M. J. Mahoney, J. Biomed.
Mater. Res. Part A 2010, 94A, 1162.
[49] X. Lu, T. H. Perera, A. B. Aria, L. A. S. Callahan, J. Exp. Pharmacol.
2018, 10, 37.
[50] L. N. Novikova, J. Pettersson, M. Brohlin, M. Wiberg, L. N. Novikov,
Biomaterials 2008, 29, 1198.
[51] R. T. H. Chan, R. A. Russell, H. Marçal, T. H. Lee, P. J. Holden, L. J.
R. Foster, Biomacromolecules 2014, 15, 339.
[52] F. Facchiano, E. Fernandez, S. Mancarella, G. Maira, M. Miscusi, D.
D’Arcangelo, G. Cimino-Reale, M. L. Falchetti, M. C. Capogrossi, R.
Pallini, J. Neurosurg. 2002, 97, 161.
[53] W. Bensaıd¨, J. T. Triﬃtt, C. Blanchat, K. Oudina, L. Sedel, H. Petite,
Biomaterials 2003, 24, 2497.
[54] V. M. Tysseling-Mattiace, V. Sahni, K. L. Niece, D. Birch, C. Czeisler,
M. G. Fehlings, S. I. Stupp, J. A. Kessler, J. Neurosci. 2008, 28, 3814.
[55] A. Göpferich, Biomaterials 1996, 17, 103.
[56] Y. Katayama, R. Montenegro, T. Freier, R. Midha, J. S. Belkas, M. S.
Shoichet, Biomaterials 2006, 27, 505.
[57] A. Hejcˇl, J. Šedý, M. Kapcalová, D. A. Toro, T. Amemori, P. Lesný, K.
Likavcˇanová-Mašínová, E. Krumbholcová, M. Prˇádný, J. Michálek,
M. Burian, M. Hájek, P. Jendelová, E. Skyková, Stem Cells Dev. 2010,
19, 1535.
[58] P. A. Ramires, M. A. Miccoli, E. Panzarini, L. Dini, C. Protopapa, J.
Biomed. Mater. Res., Part B 2005, 72B, 230.
[59] N. Comolli, B. Neuhuber, I. Fischer, A. Lowman, Acta Biomater.
2009, 5, 1046.
[60] Z. Wang, J. Nong, R. B. Shultz, Z. Zhang, T. Kim, V. J. Tom, R. K.
Ponnappan, Y. Zhong, Biomaterials 2017, 112, 62.
[61] H. Gu, Z. Yue, W. S. Leong, B. Nugraha, L. P. Tan, Regener. Med.
2010, 5, 245.
[62] M. M. Pakulska, C. H. Tator, M. S. Shoichet, Biomaterials 2017, 134,
13.
[63] M. Boido, M. Ghibaudi, P. Gentile, E. Favaro, R. Fusaro, C. Tonda-
Turo, Sci. Rep. 2019, 9, 6402.
[64] J. Chedly, S. Soares, A. Montembault, Y. von Boxberg, M. Veron-
Ravaille, C. Mouﬄe, M.-N. Benassy, J. Taxi, L. David, F. Nothias, Bio-
materials 2017, 138, 91.
[65] K. E. Crompton, J. D. Goud, R. V Bellamkonda, T. R. Gengenbach,
D. I. Finkelstein, M. K. Horne, J. S. Forsythe, Biomaterials 2007, 28,
441.
[66] J. Park, E. Lim, S. Back, H. Na, Y. Park, K. Sun, J. Biomed. Mater. Res.
Part A 2010, 93A, 1091.
[67] R. E. Thompson, J. Pardieck, L. Smith, P. Kenny, L. Crawford, M.
Shoichet, S. Sakiyama-Elbert, Biomaterials 2018, 162, 208.
[68] Z. Z. Khaing, C. E. Schmidt, Neurosci. Lett. 2012, 519, 103.
[69] M. S. Shoichet,Macromolecules 2010, 43, 581.
[70] J. Shang, Z. Shao, X. Chen, Polymer. 2008, 49, 5520.
[71] K. M. Park, S. Y. Lee, Y. K. Joung, J. S. Na, M. C. Lee, K. D. Park, Acta
Biomater. 2009, 5, 1956.
[72] C.Martínez-Ramos, L. R. Doblado, E. L.Mocholi, A. Alastrue-Agudo,
M. S. Petidier, E. Giraldo, M. M. Pradas, V. Moreno-Manzano, J. Tis-
sue Eng. Regener. Med. 2019, 13, 509.
[73] Z. Z. Khaing, N. K. Agrawal, J. H. Park, S. Xin, G. C. Plumton, K. H.
Lee, Y. J. Huang, A. L. Niemerski, C. E. Schmidt, J. W. Grau, J. Mater.
Chem. B 2016, 4, 7560.
Biotechnol. J. 2019, 14, 1900275 1900275 (7 of 8) © 2019 The Authors. Biotechnology Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.com
[74] R. Yang, C. Xu, T. Wang, Y. Wang, J. Wang, D. Quan, D. Y. B. Deng,
RSC Adv. 2017, 7, 41098.
[75] G. Perale, C. Giordano, F. Bianco, F. Rossi, M. Tunesi, F. Daniele, F.
Crivelli, M. Matteoli, M. Masi, Int. J. Artif. Organs 2011, 34, 295.
[76] N. D. Leipzig, R. G.Wylie, H. Kim,M. S. Shoichet, Biomaterials 2011,
32, 57.
[77] T. Schackel, P. Kumar, M. Günther, S. Liu, M. Brunner, B. Sandner,
R. Puttagunta, R. Müller, N. Weidner, A. Blesch, Tissue Eng., Part A
2019, 25, 522.
[78] S. Liu, B. Sandner, T. Schackel, L. Nicholson, A. Chtarto, L. Tenen-
baum, R. Puttagunta, R. Müller, N. Weidner, A. Blesch, Acta Bio-
mater. 2017, 60, 167.
[79] L. N. Novikov, L. N. Novikova, A.Mosahebi,M.Wiberg, G. Terenghi,
J. O. Kellerth, Biomaterials 2002, 23, 3369.
[80] K. H. Sitoci-Ficici, M. Matyash, O. Uckermann, R. Galli, E. Leipnitz,
R. Later, C. Ikonomidou, M. Gelinsky, G. Schackert, M. Kirsch, Acta
Neurochir. 2018, 160, 449.
[81] L. Ning, Y. Xu, X. Chen, D. J. Schreyer, J. Biomater. Sci., Polym. Ed.
2016, 27, 898.
[82] G. Palazzolo, N. Broguiere, O. Cenciarelli, H. Dermutz, M. Zenobi-
Wong, Tissue Eng., Part A 2015, 21, 2177.
[83] M. I. Günther, N.Weidner, R.Müller, A. Blesch, Acta Biomater. 2015,
27, 140.
[84] T. L. Downing, A. Wang, Z. Q. Yan, Y. Nout, A. L. Lee, M. S. Beattie,
J. C. Bresnahan, D. L. Farmer, S. Li, J. Controlled Release 2012, 161,
910.
[85] M. Di Giuseppe, N. Law, B. Webb, R. A. Macrae, L. J. Liew, T. B.
Sercombe, R. J. Dilley, B. J. Doyle, J. Mech. Behav. Biomed. Mater.
2018, 79, 150.
[86] D. Joung, V. Truong, C. C. Neitzke, S.-Z. Guo, P. J. Walsh, J. R. Monat,
F. Meng, S. H. Park, J. R. Dutton, A. M. Parr, Adv. Funct. Mater. 2018,
28, 1801850.
[87] K. Y. Lee, D. J. Mooney, Prog. Polym. Sci. 2012, 37, 106.
[88] H. Nomura, C. H. Tator, M. S. Shoichet, J. Neurotrauma 2006, 23,
496.
[89] U. Zimmermann, F. Thürmer, A. Jork, M.Weber, S. Mimietz, M. Hill-
gärtner, F. Brunnenmeier, H. Zimmermann, I. Westphal, G. Fuhr, U.
Nöth, A. Haase, A. Steinert, C. Hendrich, Ann. N. Y. Acad. Sci. 2001,
944, 199.
[90] K. Suzuki, Y. Suzuki,M. Tanihara, K. Ohnishi, T. Hashimoto, K. Endo,
Y. Nishimura, J. Biomed. Mater. Res. 2000, 49, 528.
[91] K. Suzuki, Y. Suzuki, K. Ohnishi, K. Endo, M. Tanihara, Y. Nishimura,
NeuroReport 2891, 1999, 10.
[92] I. Grulova, L. Slovinska, J. Blaško, S. Devaux, M. Wisztorski, M.
Salzet, I. Fournier, O. Kryukov, S. Cohen, D. Cizkova, Sci. Rep. 2015,
5, 13702.
[93] J. Piantino, J. A. Burdick, D. Goldberg, R. Langer, L. I. Benowitz, Exp.
Neurol. 2006, 201, 359.
[94] P. Prang, R. Müller, A. Eljaouhari, K. Heckmann, W. Kunz, T. Weber,
C. Faber, M. Vroemen, U. Bogdahn, N. Weidner, Biomaterials 2006,
27, 3560.
[95] Y. Suzuki, M. Kitaura, S. Wu, K. Kataoka, K. Suzuki, K. Endo, Y.
Nishimura, C. Ide, Neurosci. Lett. 2002, 318, 121.
[96] R. G. Ellis-Behnke, G. E. Schneider, in (Ed: S. J. Hurst), Humana
Press, Totowa, NJ 2011, pp. 259–281.
[97] P. J. Johnson, S. R. Parker, S. E. Sakiyama-Elbert, Biotechnol. Bioeng.
2009, 104, 1207.
[98] M. M. Pakulska, B. G. Ballios, M. S. Shoichet, Biomed. Mater. 2012,
7, 024101.
[99] H. Lee, R. J. McKeon, R. V Bellamkonda, Proc. Natl. Acad. Sci. U. S.
A. 2010, 107, 3340 LP.
[100] S. Kim, S. K. Nishimoto, J. D. Bumgardner, W. O. Haggard, M. W.
Gaber, Y. Yang, Biomaterials 2010, 31, 4157.
[101] Y. Kim, J.-M. Caldwell, R. V Bellamkonda, Biomaterials 2009, 30,
2582.
[102] W. M. Tian, S. P. Hou, J. Ma, C. L. Zhang, Q. Y. Xu, I. S. Lee, H. D.
Li, M. Spector, F. Z. Cui, Tissue Eng. 2005, 11, 513.
[103] E. C. Tsai, P. D. Dalton, M. S. Shoichet, C. H. Tator, Biomaterials
2006, 27, 519.
[104] N. A. Silva, M. J. Cooke, R. Y. Tam, N. Sousa, A. J. Salgado, R. L. Reis,
M. S. Shoichet, Biomaterials 2012, 33, 6345.
[105] T. Freier, R. Montenegro, H. Shan Koh, M. S. Shoichet, Biomaterials
2005, 26, 4624.
[106] S. Rochkind, A. Shahar, M. Alon, Z. Nevo,Neurol. Res. 2002, 24, 355.
[107] G. D. Sterne, R. A. Brown, C. J. Green, G. Terenghi, Eur. J. Neurosci.
1997, 9, 1388.
[108] S. Knowlton, S. Anand, T. Shah, S. Tasoglu, Trends Neurosci. 2018,
41, 31.
[109] M. Thomas, S. M. Willerth, Front. Bioeng. Biotechnol. 2017, 5, 69.
[110] I. Y. Kim, S. J. Seo, H. S. Moon, M. K. Yoo, I. Y. Park, B. C. Kim, C. S.
Cho, Biotechnol. Adv. 2008, 26, 1.
[111] S.-J. Lee, W. Zhu, N. Castro, L. G. Zhang, in (Eds: L. G. Zhang, D. L.
Kaplan), Springer International Publishing, Cham 2016, pp. 1–24.
[112] P. M. Richardson, V. M. K. Issa, A. J. Aguayo, J. Neurocytol. 1984, 13,
165.
[113] S. David, A. J. Aguayo, Science 1981, 214, 931.
[114] K. Pawar, P. Prang, R. Müller, M. Caioni, U. Bogdahn, W. Kunz, N.
Weidner, Acta Biomater. 2015, 27, 131.
[115] S. M. Willerth, S. E. Sakiyama-Elbert, Adv. Drug Delivery Rev. 2008,
60, 263.
[116] E. A. Stoll,Mol. Cell. Ther. 2014, 2, 12.
[117] M. Matyash, F. Despang, C. Ikonomidou, M. Gelinsky, Tissue Eng.,
Part C 2014, 20, 401.
[118] K. Kataoka, Y. Suzuki, M. Kitada, T. Hashimoto, H. Chou, H. Bai, M.
Ohta, S. Wu, K. Suzuki, C. Ide, Tissue Eng. 2004, 10, 493.
[119] H. Tabesh, G. Amoabediny, N. S. Nik, M. Heydari, M. Yoseﬁfard, S.
O. R. Siadat, K. Mottaghy, Neurochem. Int. 2009, 54, 73.
[120] H. Wen, W. Xiao, S. Biswas, Z.-Q. Cong, X.-M. Liu, K. S. Lam, Y.-H.
Liao, W. Deng, ACS Appl. Mater. Interfaces 2019, 11, 5821.
[121] F. Zufall, G. M. Shepherd, C. J. Barnstable, Curr. Opin. Neurobiol.
1997, 7, 404.
[122] J. H. P. Skene, Annu. Rev. Neurosci. 1989, 12, 127.
[123] P. Lu, H. Yang, L. L. Jones, M. T. Filbin, M. H. Tuszynski, J. Neurosci.
2004, 24, 6402 LP.
[124] M. Sandberg, M. Källström, J. Muhr, Nat. Neurosci. 2005, 8, 995.
[125] J. T. Neary, H. Zimmermann, Trends Neurosci. 2009, 32, 189.
[126] J. Delic, H. Zimmermann, Purinergic Signalling. 2010, 6, 417.
[127] E. Nikulina, J. L. Tidwell, H. N. Dai, B. S. Bregman, M. T. Filbin, Proc.
Natl. Acad. Sci. U. S. A. 2004, 101, 8786.
[128] T. Führmann, P. N. Anandakumaran,M. S. Shoichet, Adv. Healthcare
Mater. 2017, 6, 1601130.
Biotechnol. J. 2019, 14, 1900275 1900275 (8 of 8) © 2019 The Authors. Biotechnology Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
